Sistema de Salut de Catalunya
Institut Català de la Salut
[Mateos-Muñoz B] Hospital Universitario Ramón y Cajal, CIBEREHD, IRYCIS, Universidad de Alcalá, Madrid, Spain. [Buti M, Marcos-Fosch C] Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBEREHD, Barcelona, Spain. [Fernández Vázquez I] Gastroenterology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain. [Hernández Conde M] Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. [Bernal-Monterde V] Gastroenterology Department, Hospital Miguel Servet, Zaragoza, Spain. [Díaz-Fontenla F] Gastroenterology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-06-20T07:31:56Z
2023-06-20T07:31:56Z
2023-06
COVID-19; Hepatitis B; Tenofovir
COVID-19; Hepatitis B; Tenofovir
COVID-19; Hepatitis B; Tenofovir
Background and Aims HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV). Methods Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19. Results Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04–0.67, p = 0.01). Conclusion Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.
Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. No funding sources needed.
Article
Published version
English
Medicaments antivírics - Ús terapèutic; Hepatitis B - Tractament; COVID-19 (Malaltia) - Tractament; DISEASES::Virus Diseases::DNA Virus Infections::Hepadnaviridae Infections::Hepatitis B::Hepatitis B, Chronic; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Hepadnaviridae::hepatitis B::hepatitis B crónica; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
Springer
Digestive Diseases and Sciences;68(6)
https://doi.org/10.1007/s10620-022-07817-w
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3440]
